Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell NewsCorvus Pharmaceuticals, Inc. announced that it has discontinued its Phase III study of mupadolimab for COVID-19 due to positive trends exhibited by COVID-19 vaccines in lowering serious infection and hospitalizations.
[Corvus Pharmaceuticals, Inc.]
Home Newsletters Immunology of Infectious Disease News Corvus Pharmaceuticals Discontinues Phase III Study of Mupadolimab (Anti-CD73) for COVID-19 Due...
